Vivoryon Therapeutics NV (VVY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has a cash flow conversion efficiency ratio of -0.838x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.96 Million ≈ $-4.63 Million USD) by net assets (€4.73 Million ≈ $5.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vivoryon Therapeutics NV - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Vivoryon Therapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Vivoryon Therapeutics NV carry for a breakdown of total debt and financial obligations.
Vivoryon Therapeutics NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivoryon Therapeutics NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
0.381x |
|
Domiki Kritis S.A.
AT:DOMIK
|
0.028x |
|
Puloon Technology Inc
KQ:094940
|
-0.019x |
|
Mishorim Real Estate Investments
TA:MSHR
|
-0.017x |
|
Aurumin Ltd
AU:AUN
|
0.017x |
|
Saeron Auto
KO:075180
|
-0.002x |
|
AViTA Corporation
TWO:4735
|
0.043x |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
0.023x |
Annual Cash Flow Conversion Efficiency for Vivoryon Therapeutics NV (2011–2025)
The table below shows the annual cash flow conversion efficiency of Vivoryon Therapeutics NV from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see VVY market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.73 Million ≈ $5.53 Million |
€-8.46 Million ≈ $-9.88 Million |
-1.789x | +26.49% |
| 2024-12-31 | €7.88 Million ≈ $9.21 Million |
€-19.17 Million ≈ $-22.42 Million |
-2.433x | -196.88% |
| 2023-12-31 | €26.28 Million ≈ $30.73 Million |
€-21.54 Million ≈ $-25.18 Million |
-0.820x | +0.32% |
| 2022-12-31 | €26.51 Million ≈ $30.99 Million |
€-21.79 Million ≈ $-25.48 Million |
-0.822x | -20.93% |
| 2021-12-31 | €16.56 Million ≈ $19.36 Million |
€-11.26 Million ≈ $-13.16 Million |
-0.680x | -27.23% |
| 2020-12-31 | €26.22 Million ≈ $30.66 Million |
€-14.01 Million ≈ $-16.38 Million |
-0.534x | -96.41% |
| 2019-12-31 | €42.66 Million ≈ $49.88 Million |
€-11.61 Million ≈ $-13.57 Million |
-0.272x | +95.22% |
| 2018-12-31 | €1.23K ≈ $1.44K |
€-6.99K ≈ $-8.18K |
-5.686x | -318.73% |
| 2017-12-31 | €8.92K ≈ $10.43K |
€-12.12K ≈ $-14.17K |
-1.358x | -67.77% |
| 2016-12-31 | €16.38K ≈ $19.15K |
€-13.26K ≈ $-15.50K |
-0.809x | -7.50% |
| 2015-12-31 | €16.13K ≈ $18.86K |
€-12.15K ≈ $-14.20K |
-0.753x | -13.56% |
| 2014-12-31 | €15.97K ≈ $18.67K |
€-10.59K ≈ $-12.38K |
-0.663x | -132.85% |
| 2013-12-31 | €-4.22 Million ≈ $-4.94 Million |
€-8.53 Million ≈ $-9.97 Million |
2.018x | +189.94% |
| 2012-12-31 | €5.37 Million ≈ $6.27 Million |
€-12.04 Million ≈ $-14.08 Million |
-2.244x | -134.20% |
| 2011-12-31 | €14.95 Million ≈ $17.47 Million |
€-14.32 Million ≈ $-16.74 Million |
-0.958x | -- |
About Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more